Aktien Sensor

Becton Dickinson & Co’s stock price has fluctuated within a 52-week range, currently trading at $171.03 with a relatively stable price movement.

Becton Dickinson has launched its revolutionary FACSDiscover A8 cell analyzer, a cutting-edge device that promises to transform research and development in the medical technology sector.

Becton Dickinson & Co.’s stock price has declined due to downgrades from Wall Street analysts, who are concerned about the company’s ability to meet growth targets following its revised fiscal guidance.

Becton Dickinson & Co has launched a game-changing bioabsorbable mesh for umbilical hernia repair, which could positively impact its stock price and drive growth in the medical technology sector.

Becton Dickinson & Co’s Q1 2025 earnings exceeded expectations, with the company’s revenue growth and stable financial position solidifying its position as a leader in the medical technology space.

Becton Dickinson & Co. has partnered with BCAL Diagnostics Limited to launch a non-invasive breast cancer diagnostic test, BREASTEST plus, which may positively impact BDX’s stock price.

Becton Dickinson’s stock is a high-stakes investment opportunity, with both optimistic and pessimistic views on its future performance, leaving investors to weigh the risks and rewards.

Becton Dickinson & Co’s stock price has been rising, but its high valuation and involvement of activist investor Starboard raise concerns about its future stability.